Stock analysts at HC Wainwright initiated coverage on shares of Synthetic Biologics (NYSEAMERICAN:SYN) in a research note issued to investors on Friday, The Fly reports. The firm set a “buy” rating on the stock.
SYN has been the topic of several other research reports. Zacks Investment Research raised Synthetic Biologics from a “sell” rating to a “hold” rating in a research note on Saturday, February 24th. Griffin Securities lowered Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 9th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $2.63.
Get Synthetic Biologics alerts:
Shares of Synthetic Biologics opened at $0.25 on Friday, according to Marketbeat.com. Synthetic Biologics has a 12-month low of $0.23 and a 12-month high of $0.27.
Synthetic Biologics (NYSEAMERICAN:SYN) last issued its quarterly earnings results on Tuesday, May 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC raised its position in shares of Synthetic Biologics by 312.1% during the fourth quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock worth $122,000 after purchasing an additional 183,120 shares during the period. Virtu Financial LLC raised its position in shares of Synthetic Biologics by 256.1% during the fourth quarter. Virtu Financial LLC now owns 299,577 shares of the company’s stock worth $152,000 after purchasing an additional 215,440 shares during the period. 683 Capital Management LLC acquired a new stake in shares of Synthetic Biologics during the fourth quarter worth about $762,000. Finally, Blair William & Co. IL raised its position in shares of Synthetic Biologics by 14.8% during the first quarter. Blair William & Co. IL now owns 1,980,857 shares of the company’s stock worth $631,000 after purchasing an additional 255,096 shares during the period.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.